"With this adjustment to earnings guidance and the dividend increase, we're sending a clear message of confidence: We expect to be able to continue to reward our shareholders for their support, well into the future," said Mr. Cornelius.
Research and Development Update
In addition to discussing progress in transforming the R&D organization into a next-generation BioPharma model and executing its biologic strategy, the company also will provide an update on key late and early stage compounds in its pipeline. The company will continue to focus its efforts on serious disease - in both specialty areas and high prevalence illnesses - where there is significant unmet medical need. Senior members of the R&D organization will outline the strategy of building pipelines within products by broadening their clinical use through multiple indications.
Specific updates will focus on the company's late-stage programs in
oncology, diabetes, cardiovascular disease and solid organ transplant
-- developmental diabetes compounds saxagliptin, a DPP4-inhibitor, and
dapagliflozin, a novel SGLT-2 inhibitor, both of which are being
developed in partnership with AstraZeneca PLC; the company reiterated
its plan to submit saxagliptin for filing with the U.S. Food and Drug
Administration (FDA) in 2008;
-- two cancer drugs: the internally developed and recently approved
Ixempra (ixabepilone), a new cytotoxic designed to overcome drug
resistance; and ipilimumab (MDX-010), a potential new immunotherapy
-- an internally discovered biologic investigational compound,
belatacept, a novel co-stimulation blocker under development to
replace cornerstone therapy in solid organ transplantation, which the
company expects to submit to the FDA for filing in the
|SOURCE Bristol-Myers Squibb Company|
Copyright©2007 PR Newswire.
All rights reserved